Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women's Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
- 09/06/2024
|
Dorsata's Alliance on Adnexal Masses to Support Aspira Stock
- AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.
- 09/02/2024
|
Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Nicole Sandford - CEO and Director Sandy Milligan - President Conference Call Participants Ross Osborn - Cantor Fitzgerald Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen. And welcome to Aspira Women's Health, Incorporated Second Quarter 2024 Earnings Conference Call.
- 08/12/2024
|
Aspira (AWH) Reports Q2 Loss, Misses Revenue Estimates
- Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago.
- 08/12/2024
|
Aspira Women's Health Reports Second Quarter 2024 Financial Results
- Q2 2024 OvaSuite S M revenue of $2.4 million and volume of 6,471 units
- 08/12/2024
|
Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference
- AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner's in Women's Health (NPWH) Woman's Healthcare Conference being held on September 25-28, 2024, in Chicago, IL. Presentation details are as follows:
- 08/05/2024
|
AWH ANNOUNCES Q2 2024 FINANCIAL RESULTS
- Achieved $141.5M Net Revenue in Q2 2024 , a 15% Increase Year-Over-Year Reported $28.3 million in Adjusted EBITDA, a 33% Increase Year-Over-Year Generated Positive Cash from Operations and Free Cash Flow NEW YORK , Aug. 5, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended June 30, 2024 ("Q2 2024"). Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP") and all currency is in U.S. dollars.
- 08/05/2024
|
Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing
- AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company's common stock and accompanying warrants to purchase an equal number of shares for gross proceeds of approximately $1.9 million. Aspira has the potential to receive additional gross proceeds of up to $2.8 million, before deducting offering expenses, upon the full cash exercise of warrants issued in the private placement.
- 07/09/2024
|
AWH to Hold Second Quarter 2024 Earnings Conference Call on Monday, August 5, 2024
- NEW YORK , July 8, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a leading multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Monday, August 5, 2024, at 8:30 AM ET following the release of its second quarter 2024 financial results. The earnings conference call may be accessed by dialing 1 (888) 390-0605.
- 07/08/2024
|
Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing
- AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal number of shares of Common Stock (“Warrants”) at a combined offering price of $1.53 per share and warrant through a private placement financing (the “Offering”). Aspira anticipates the gross proceeds from the Offering will be approximately $1.935 million, before deducting offering expenses. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.
- 07/01/2024
|
Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates
- Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024. Product volume continued its sustained monthly gains, growing by more than 26% in May 2024 compared to January 2024.
- 06/13/2024
|
Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21
- AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.
- 05/16/2024
|
Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call.
- 05/15/2024
|
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
- Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago.
- 05/15/2024
|
Aspira Women's Health Reports First Quarter 2024 Financial Results
- Q1 2024 OvaSuite S M revenue of $2.2 million and volume of 5,829 units
- 05/15/2024
|
UPDATE -- Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
- AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
- 05/08/2024
|
Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
- AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
- 05/08/2024
|
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
- Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid
- 04/09/2024
|
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
- Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
- 2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023. “We made a great deal of progress in 2023.
- 03/28/2024
|
Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference
- AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
- 03/21/2024
|
Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
- AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows:
- 03/11/2024
|
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
- AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
- 02/22/2024
|
Aspira Women's Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
- AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
- 02/12/2024
|
Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
- AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company's product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here.
- 12/19/2023
|
Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
- AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan's Healthcare Conference Week 2024. Nicole Sandford, President and Chief Executive Officer, in addition to Torsten Hombeck, Ph.D., Chief Financial Officer from the management team will be in attendance at the following corporate access and partnering events:
- 12/14/2023
|
Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
- Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma
- 12/06/2023
|
Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
- California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test
- 11/28/2023
|
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
- CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024.
- 11/27/2023
|
Aspira Women's Health Inc. (AWH) Q3 2023 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 11/13/2023
|
Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
- The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period
- 11/09/2023
|
Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
- Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests
- 10/25/2023
|
Aspira Women's Health to Present at the BioVenture Nexus Conference
- The conference is taking place on October 5-6, 2023, in Los Angeles, CA The conference is taking place on October 5-6, 2023, in Los Angeles, CA
- 09/29/2023
|
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
- Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.
- 09/14/2023
|
All You Need to Know About Aspira (AWH) Rating Upgrade to Buy
- Aspira (AWH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/12/2023
|
Eleventh-Hour Climbers: 7 Stocks Gearing Up for a Late Summer Surge
- While some publicly traded enterprises left no doubt as to their trajectory, a few others are just now benefiting from a late summer stock surge. Better late than never, though.
- 09/03/2023
|
Aspira Women's Health Inc. (AWH) Q2 2023 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Nicole Sandford – President and Chief Executive Officer Torsten Hombeck – Chief Financial Officer Conference Call Participants Sally Yanchus – Water Tower Research Andrew Brackmann – William Blair Operator Good afternoon, ladies and gentlemen, and welcome to Aspira's Women's Health, Incorporated Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
- 08/14/2023
|
Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023
- AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14, 2023. Management will host a conference call to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows:
- 07/31/2023
|
Aspira Women's Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference
- AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it would present at the upcoming 2023 American College of Obstetricians and Gynecologists (“ACOG”) Annual Clinical & Scientific Conference being held in Baltimore, MD on May 19-21, 2023.
- 05/19/2023
|
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
- Aspira (AWH) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.
- 05/11/2023
|
New Strong Buy Stocks for May 11th
- AMEH, PYCR, AWH, SAND and MCD have been added to the Zacks Rank #1 (Strong Buy) List on May 11, 2023.
- 05/11/2023
|
Aspira Women's Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023
- Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history
- 04/27/2023
|
What Makes Aspira (AWH) a New Buy Stock
- Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/27/2023
|
Aspira Women's Health Inc. (AWH) Q4 2022 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Nicole Sandford - President & Chief Executive Officer Ryan Phan - Chief Scientific Officer & Chief Operating Officer Marlene McLennan - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair Operator Good morning ladies and gentlemen and welcome to Aspira Women's Health, Inc. Fourth Quarter and Year-End 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
- 03/22/2023
|
Aspira (AWH) Reports Q4 Loss, Misses Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of 33.33% and 10.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/22/2023
|
Aspira Women's Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023
- AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the call are below:
- 03/03/2023
|
Aspira Women's Health Inc. (AWH) Q3 2022 Earnings Call Transcript
- Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Robert Beechey - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair & Company Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health Incorporated Third Quarter 2022 Conference Call. My name is David, and I will be your coordinator for the call today.
- 11/10/2022
|
Down 38.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspira (AWH)
- The heavy selling pressure might have exhausted for Aspira (AWH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 08/24/2022
|
Aspira Women's Health, Inc. (AWH) CEO Nicole Sandford on Q2 2022 Results - Earnings Call Transcript
- Aspira Women's Health, Inc. (NASDAQ:AWH ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Robert Beechey - Chief Financial Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Inc. Second Quarter 2022 Conference Call. My name is Vikram and I will be your coordinator for the call today.
- 08/10/2022
|
Aspira Women's Health, Inc. (AWH) CEO Nicole Sandford on Q1 2022 Results - Earnings Call Transcript
- Aspira Women's Health, Inc. (NASDAQ:AWH ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Nicole Sandford - President, Chief Executive Officer and Director Robert Beechey - Chief Financial Officer Michael Newton - Head, Commercial Conference Call Participants Brian Weinstein - William Blair & Company Ross Osborn - Cantor Fitzgerald & Co. Nicole Sandford Thank you, operator, and thank you to all of you for joining us today. I'll start with a business update before I hand the call over to Bob to review our Q1 financial performance.
- 05/11/2022
|
Aspira (AWH) Reports Q1 Loss, Misses Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of 0% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2022
|
Aspira Women's Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11
- AUSTIN, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the first quarter ended March 31, 2022 before the market open on Wednesday, May 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:
- 04/29/2022
|
Aspira Women's Health Inc. (AWH) CEO Nicole Sanford on Q4 2021 Results - Earnings Call Transcript
- Aspira Women's Health Inc. (AWH) CEO Nicole Sanford on Q4 2021 Results - Earnings Call Transcript
- 03/23/2022
|
Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/23/2022
|
Aspira Women's Health to Announce Year End 2021 Financial Results and Host Conference Call on Wednesday, March 23
- AUSTIN, Texas, March 15, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that the company will report its financial results for the year ended December 31, 2021 before the market open on Wednesday, March 23, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:
- 03/15/2022
|
Best Penny Stocks To Buy For A Short Squeeze? 5 To Watch Today
- Short squeeze penny stocks to watch today. The post Best Penny Stocks To Buy For A Short Squeeze?
- 11/22/2021
|
Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q3 2021 Earnings Call Transcript
- Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q3 2021 Earnings Call Transcript
- 11/10/2021
|
Aspira (AWH) Reports Q3 Loss, Tops Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of -12.50% and 11.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
5 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
- 5 short squeeze penny stocks to buy for under $5. Are they worth the risk?
- 11/05/2021
|
Aspira Women's Health Inc. to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
- AUSTIN, Texas, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021.
- 09/21/2021
|
Aspira Women's Health Kicks Off Ovarian Cancer Awareness Month by Further Establishing Itself as a Thought Leader in Ovarian Cancer
- Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer Signals Call to Action for Immediate Progress in Conquering Ovarian Cancer
- 09/09/2021
|
Aspira Women's Health's (AWH) CEO Valerie Palmieri on Q2 2021 Results - Earnings Call Transcript
- Aspira Women's Health's (AWH) CEO Valerie Palmieri on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Aspira (AWH) Reports Q2 Loss, Tops Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of 0.00% and 5.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Analysts Estimate Aspira (AWH) to Report a Decline in Earnings: What to Look Out for
- Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/05/2021
|
Aspira Women's Health (AWH) is Oversold: Can It Recover?
- Aspira Women's Health (AWH) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- 07/15/2021
|
UPDATE -- Aspira Women's Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines
- AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) today announced its OVA1® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health's Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation's largest health care organizations. AIM's mission is to promote appropriate, safe, and affordable health care. As one of the nation's leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.
- 07/08/2021
|
Aspira Women's Health Inc. to Participate in the William Blair Growth Stock Conference
- AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below:
- 05/19/2021
|
Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q1 2021 Results - Earnings Call Transcript
- Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
- Aspira (AWH) delivered earnings and revenue surprises of 79.17% and 6.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Aspira Women's Health Reports First Quarter 2021 Financial Results
- Conference call scheduled for today, May13 at 4:30 p.m. ET Conference call scheduled for today, May13 at 4:30 p.m. ET
- 05/13/2021
|
Aspira Women's Health, Inc. Expands Leadership Team with Industry Veteran
- New Team Addition Is a Thought Leader in Reimbursement and Diagnostics New Team Addition Is a Thought Leader in Reimbursement and Diagnostics
- 05/11/2021
|
Earnings Preview: Aspira (AWH) Q1 Earnings Expected to Decline
- Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2021
|
What Traders Can Expect From Small Caps in 2021
- Below is a repost of an article from Benzina.com, which features Schaeffer's V.P.
- 03/28/2021
|
Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q4 2020 Results - Earnings Call Transcript
- Aspira Women's Health Inc. (AWH) CEO Valerie Palmieri on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Aspira Women's Health Reports Fourth Quarter and Full Year 2020 Financial Results
- Conference Call scheduled for today, March 25th at 4:30 p.m. ET Conference Call scheduled for today, March 25th at 4:30 p.m. ET
- 03/25/2021
|
Analysts Estimate Aspira (AWH) to Report a Decline in Earnings: What to Look Out for
- Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/18/2021
|
Aspira Women's Health Inc. Appoints Nicole Sandford to its Board of Directors
- AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced the appointment of Ms. Nicole Sandford to its Board of Directors.
- 02/22/2021
|
Aspira Women's Health, Inc. to Participate in BTIG's Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
- AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced management will participate and present in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference taking place on February 17-19. Details for the event are below:
- 02/12/2021
|
Aspira Women's Health, Inc. to add NCCN Management Recommendations to its Proprietary Aspira GenetiX™ Clinical Report
- Aspira will incorporate Management Recommendations from the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in the Aspira GenetiX report Aspira will incorporate Management Recommendations from the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in the Aspira GenetiX report
- 02/10/2021
|
Aspira Women's Health Inc. Announces Pricing of $45 Million Public Offering of Common Stock
- AUSTIN, Texas, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Aspira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Aspira.
- 02/04/2021
|
Aspira Women's Health Inc. Announces Proposed Public Offering of Common Stock
- AUSTIN, Texas, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aspira is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. All of the shares will be offered by Aspira.
- 02/03/2021
|
Aspira Women's Health, Inc. to Participate in Virtual Investor Events
- Aspira to participate in the 10 th Annual LifeSci Advisors Corporate Access Event and Biotech Showcase™ from January 6 – 15 th , 2021
- 01/04/2021
|
Reviewing Aspira Women's Health (AWH) & Its Competitors
- Aspira Women's Health (NASDAQ: AWH) is one of 34 public companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Aspira Women's Health to related companies based on the strength of its institutional ownership, analyst recommendations, dividends, valuation, risk, profitability and earnings. Institutional & Insider Ownership 22.9% of […]
- 10/22/2020
|
COVID-19 Recovery Analysis: Spa Market | Growing Wellness Tourism Industry to Boost the Market Growth | Technavio
- The Global Spa Market will grow by $ 25.48 bn during 2020-2024
- 10/21/2020
|
UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results
- Conference Call scheduled for today, August 13th at 4:30 p.m. ETAUSTIN, Texas, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. In fact, our test volume was 12% higher in the first half of 2020 than in the same period in 2019. Delivering surgical triage results to physicians during this period of operating room rationing and backlog is essential,” said Valerie Palmieri, Chief Executive Officer of ASPIRA. “We are seeing patients return to their providers and began to see the corresponding volume restoration in the second quarter. OVANex™ and EndoCheck™ study site recruitment has also continued to improve.”Recent Corporate Highlights Year over Year Results – Second Quarter 2020 versus Second Quarter 2019: * OVA1 product volume decreased 21% to 2,458 units down from 3,129 units in the second quarter of last year * Product revenue decreased 32% to $743 thousand down from $1.1 million in the second quarter of last year * Total number of customers decreased by 18% compared to the second quarter of last year * New customers decreased by 56% compared to the second quarter of last year; * Total number of repeat customers were 85% in the second quarter of this year compared to 73% for the same period in the prior yearYear over Year Results – First Half 2020 versus First Half 2019: * OVA1 product volume increased 12% to 6,112 units up from 5,442 units in the first half of last year * Product revenue increased 4% to $1,953 thousand up from $1,879 thousand in the first half of last year * Total number of customers increased by 11% compared to the same period last year * New customers decreased by 25% compared to the same period last yearCOVID-19 TestingIn the second quarter of 2020, we began offering COVID-19 antibody testing and began preparations for offering COVID-19 antigen testing. Each test is or will be a part of our pre-surgical risk test offering, which also includes OVA1plus test, additional tumor proteins and genetics. * On June 10th, we announced we had completed laboratory validation of the antibody test, as well as laboratory validation of several additional oncology biomarkers. We are offering the Roche Elecsys Anti-SARS-Co-V-2 Assay which has a 99.81% sensitivity and 100% specificity. * Our planned offering of COVID-19 antigen testing has been postponed due to manufacturer instrumentation delays. We are now planning to offer this test in late third quarter or early fourth quarter 2020. Sales Contact and Virtual Ordering ProcessWe have developed and launched our Virtual Sales and Marketing Strategy. In addition, we have developed a process to facilitate physician on-line ordering to enable a more efficient virtual go to market strategy. We are refining our approach to include more targeted use of in-house sales personnel to enhance the effectiveness of sales representatives in the field and to accommodate practitioners who only allow limited onsite visits.Payroll Protection Program FinancingDuring the second quarter, we were granted a loan pursuant to the Payroll Protection Program (“PPP”) which was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which is being used primarily to fund payroll in the amount of approximately $1M. We are using the proceeds of the loan in a manner that we believe will qualify us for complete forgiveness of the principal of the loan under the terms of the CARES Act and the PPP. The Company plans to apply for loan forgiveness in the third quarter 2020.State of Connecticut FinancingWe previously announced a $4M loan from the State of Connecticut, $2M of which we received in 2016. The loan agreement provides that we will be eligible to receive the additional $2M based on target revenue and a revised target employment milestone. We achieved the target employment milestone as well as revenue targets. We have filed the required application and are awaiting final approval for the funding.Private PlacementIn July 2020, we sold shares of our common stock in a private placement generating approximately $11 million of gross proceeds prior to transaction costs. This financing, together with cash on hand at the end of the second quarter and expected additional funding from the State of Connecticut discussed above will enable us to execute on our product pipeline and continue to drive incremental growth and refinement of our commercial team. Second Quarter Financial Highlights: * Revenue on a per test performed basis for OVA1 revenue was $295 in the second quarter of 2020 compared to $324 in the first quarter of 2020. Included in the Q2 revenue and the average unit price were approximately $79 thousand in one-time revenue adjustments relating to prior periods which account for $32 per test of the decline. We are realizing a higher revenue per test for our new contract price from CIGNA, effective April 1, 2020, which was slightly offset by a temporary decrease in the mix of Medicare patients who, given their demographic, had reduced visits to doctors. * The number of OVA1 tests performed decreased 21% to 2,458 during the second quarter of 2020 compared to 3,129 for the same period in 2019. * Gross profit on OVA1 product revenue was $268 thousand (a 37% profit margin) for the second quarter of 2020 compared to $491 thousand for the same period in 2019 (a 45% profit margin). * Research and development expenses for the second quarter of 2020 were $380 thousand, an increase of $155 thousand compared to the same period in 2019. This increase was primarily due to the launch of clinical studies, the development of OVANex™, our third-generation serial monitoring product, as well as investments in bioinformatics and our cloud-based platform, ASPiRA GenetiX Technology Transfer. * Sales and marketing expenses for the second quarter of 2020 were $1.7M compared to $2.8M in the same period in 2019. This decrease was primarily due to reduced commission payments and personnel-related costs as well as reductions in consulting and travel due to the COVID-19 pandemic compared to those in the same period in 2019. * General and administrative expenses for the second quarter of 2020 were $1.9M compared to $1.5M for the same period in 2019. This increase was primarily due to an increase in headcount and personnel-related expenses as well as legal expenses. * The cash balance at June 30, 2020 was $10.9 million and cash utilization in the second quarter of 2020 was $3.3M, offset by cash received for the exercise of warrants of $5.1M and the receipt of the $1.0 million PPP loan. Cash utilization was lower than the preceding quarter primarily due to less expenses incurred as a result of COVID.Conference Call and WebcastASPIRA will host a call today at 4:30 p.m. Eastern Daylight Time to discuss results followed by a question and answer period.Thursday, August 13th @ 4:30pmET Domestic:877-407-4018 International:201-689-8471 Conference ID:13699543 Webcast: http://public.viavid.com/index.php?id=140750 About Aspira Women’s Health Inc. ASPIRA is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment ASPIRA has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.Visit our website for more information about our products at www.aspirawh.com. Forward-Looking Statements This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expected timing and receipt of proceeds from the State of Connecticut Department of Economic Development loan, expectations regarding the forgiveness of the PPP loan, anticipated use of capital and its effects and plans to begin offering COVID-19 antigen testing. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in business, including those described in the section entitled “Risk Factors” in ASPIRA’s Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by the section entitled “Risk Factors” in ASPIRA’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The events and circumstances reflected in ASPIRA’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.
- 08/14/2020
|
Aspira Women's Health, Inc. (AWH) CEO Valerie Palmieri on Q2 2020 Results - Earnings Call Transcript
- Aspira Women's Health, Inc. (NASDAQ:AWH) Q2 2020 Earnings Conference Call August 13, 2020, 16:30 ET Company Participants Valerie Palmieri - CEO, President & Director Lesley Northrop - Global Medical Director, Genetic Services Robert Beechey - CFO Conference Call Participants Andrew Brackmann - William Blair & Company Presentation Operator Good afternoon, and welcome to Aspira Women's Health Second Quarter 2020 Conference Call.
- 08/13/2020
|
Aspira Women’s Health Reports Second Quarter 2020 Financial Results
- Conference Call scheduled for today, August 13th at 4:30 p.m. ETAUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020.“Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. In fact, our test volume was 12% higher in the first half of 2020 than in the same period in 2019. Delivering surgical triage results to physicians during this period of operating room rationing and backlog is essential,” said Valerie Palmieri, Chief Executive Officer of ASPIRA. “We are seeing patients return to their providers and began to see the corresponding volume restoration in the second quarter. OVANex™ and EndoCheck™ study site recruitment has also continued to improve.”Recent Corporate Highlights Year over Year Results – Second Quarter 2020 versus Second Quarter 2019: * OVA1 product volume decreased 21% to 2,458 units down from 3,129 units in the second quarter of last year * Product revenue decreased 32% to $743 thousand down from $1.1 million in the second quarter of last year * Total number of customers decreased by 18% compared to the second quarter of last year * New customers decreased by 56% compared to the second quarter of last year; * Total number of repeat customers were 85% in the second quarter of this year compared to 73% for the same period in the prior yearYear over Year Results – First Half 2020 versus First Half 2019: * OVA1 product volume increased 12% to 6,112 units up from 5,442 units in the first half of last year * Product revenue increased 4% to $1,953 thousand up from $1,879 thousand in the first half of last year * Total number of customers increased by 11% compared to the same period last year * New customers decreased by 25% compared to the same period last yearCOVID-19 TestingIn the second quarter of 2020, we began offering COVID-19 antibody testing and began preparations for offering COVID-19 antigen testing. Each test is or will be a part of our pre-surgical risk test offering, which also includes OVA1plus test, additional tumor proteins and genetics. * On June 10th, we announced we had completed laboratory validation of the antibody test, as well as laboratory validation of several additional oncology biomarkers. We are offering the Roche Elecsys Anti-SARS-Co-V-2 Assay which has a 99.81% sensitivity and 100% specificity. * Our planned offering of COVID-19 antigen testing has been postponed due to manufacturer instrumentation delays. We are now planning to offer this test in late third quarter or early fourth quarter 2020. Sales Contact and Virtual Ordering ProcessWe have developed and launched our Virtual Sales and Marketing Strategy. In addition, we have developed a process to facilitate physician on-line ordering to enable a more efficient virtual go to market strategy. We are refining our approach to include more targeted use of in-house sales personnel to enhance the effectiveness of sales representatives in the field and to accommodate practitioners who only allow limited onsite visits.Payroll Protection Program FinancingDuring the second quarter, we were granted a loan pursuant to the Payroll Protection Program (“PPP”) which was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which is being used primarily to fund payroll in the amount of approximately $1M. We are using the proceeds of the loan in a manner that we believe will qualify us for complete forgiveness of the principal of the loan under the terms of the CARES Act and the PPP. The Company plans to apply for loan forgiveness in the third quarter 2020.State of Connecticut FinancingWe previously announced a $4M loan from the State of Connecticut, $2M of which we received in 2016. The loan agreement provides that we will be eligible to receive the additional $2M based on target revenue and a revised target employment milestone. We achieved the target employment milestone as well as revenue targets. We have filed the required application and are awaiting final approval for the funding.Private PlacementIn July 2020, we sold shares of our common stock in a private placement generating approximately $11 million of gross proceeds prior to transaction costs. This financing, together with cash on hand at the end of the second quarter and expected additional funding from the State of Connecticut discussed above will enable us to execute on our product pipeline and continue to drive incremental growth and refinement of our commercial team. Second Quarter Financial Highlights: * Revenue on a per test performed basis for OVA1 revenue was $295 in the second quarter of 2020 compared to $324 in the first quarter of 2020. Included in the Q2 revenue and the average unit price were approximately $79 thousand in one-time revenue adjustments relating to prior periods which account for $32 per test of the decline. We are realizing a higher revenue per test for our new contract price from CIGNA, effective April 1, 2020, which was slightly offset by a temporary decrease in the mix of Medicare patients who, given their demographic, had reduced visits to doctors. * The number of OVA1 tests performed decreased 21% to 2,458 during the second quarter of 2020 compared to 3,129 for the same period in 2019. * Gross profit on OVA1 product revenue was $268 thousand (a 37% profit margin) for the second quarter of 2020 compared to $491 thousand for the same period in 2019 (a 45% profit margin). * Research and development expenses for the second quarter of 2020 were $380 thousand, an increase of $155 thousand compared to the same period in 2019. This increase was primarily due to the launch of clinical studies, the development of OVANex™, our third-generation serial monitoring product, as well as investments in bioinformatics and our cloud-based platform, ASPiRA GenetiX Technology Transfer. * Sales and marketing expenses for the second quarter of 2020 were $1.7M compared to $2.8M in the same period in 2019. This decrease was primarily due to reduced commission payments and personnel-related costs as well as reductions in consulting and travel due to the COVID-19 pandemic compared to those in the same period in 2019. * General and administrative expenses for the second quarter of 2020 were $1.9M compared to $1.5M for the same period in 2019. This increase was primarily due to an increase in headcount and personnel-related expenses as well as legal expenses. * The cash balance at June 30, 2020 was $10.9 million and cash utilization in the second quarter of 2020 was $3.3M, offset by cash received for the exercise of warrants of $5.1M and the receipt of the $1.0 million PPP loan. Cash utilization was lower than the preceding quarter primarily due to less expenses incurred as a result of COVID.Conference Call and WebcastASPIRA will host a call today at 4:30 p.m. Eastern Daylight Time to discuss results followed by a question and answer period.Thursday, August 13th @ 4:30pmET Domestic:877-407-4018 International:201-689-8471 Conference ID:13699543 Webcast:http://public.viavid.com/index.php?id=138240 About Aspira Women’s Health Inc. ASPIRA is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment ASPIRA has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.Visit our website for more information about our products at www.aspirawh.com. Forward-Looking Statements This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expected timing and receipt of proceeds from the State of Connecticut Department of Economic Development loan, expectations regarding the forgiveness of the PPP loan, anticipated use of capital and its effects and plans to begin offering COVID-19 antigen testing. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in business, including those described in the section entitled “Risk Factors” in ASPIRA’s Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by the section entitled “Risk Factors” in ASPIRA’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The events and circumstances reflected in ASPIRA’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.
- 08/13/2020
|
Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th
- AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.Thursday, August 13th @ 4:30pm ET Domestic:201-689-8472 International:877-407-4021 Conference ID:13706942 Webcast:http://public.viavid.com/index.php?id=140750 About Aspira Women’s Health Inc. Aspira Women’s Health, Inc. (formerly known as, Vermillion Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577 Arr@lifesciadvisors.com
- 07/31/2020
|
Insider Buying: Jack Schuler Just Spent US$8.0m On Aspira Women's Health Inc. (NASDAQ:AWH) Shares
- Those following along with Aspira Women's Health Inc. (NASDAQ:AWH) will no doubt be intrigued by the recent purchase...
- 07/08/2020
|
Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million
- The closing of the private placement is expected to occur on July 6, 2020, subject to customary closing conditions. At the closing, ASPIRA will receive approximately $11 million in gross proceeds, before transaction costs. ASPIRA intends to use the net proceeds from the private placement for sales and marketing, working capital and other general corporate purposes, including investing in additional key strategic hires and product portfolio expansion.
- 07/01/2020
|
Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring
- Aspira Women’s Health, Inc. (AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing ovarian cancer risk in women who have an adnexal mass and a high probability for developing the disease.
- 06/29/2020
|
Fairfax Financial Holdings' (Prem Watsa) Annual Chairman Letter To Shareholders 2017
|
20 Stocks Moving In Friday's Pre-Market Session
|
AXIS Capital to Buy Novae & Consolidate Lloyd's Presence
|
Allied World Assurance Company Holdings Merger Deal with Fiarfax Financial Extended to July 5 from June 30th
|
Merger Monday: 9 M&A Firecrackers Ahead Of Market Holiday
|
Allied World Accepts Final Fairfax Financial Exchange Ratio
|
Carlson Capital L P Buys Mobileye NV, Macy's Inc, VCA Inc, Sells St Jude Medical Inc, Endurance ...
|
Carlson Capital L P Buys Mobileye NV, Macy's Inc, VCA Inc, Sells St Jude Medical Inc, Endurance ...
|
Alpine Partners VI, LLC Buys Mobileye NV, VCA Inc, Allied World Assurance Co Holdings AG, Sells ...
|
Gabelli Securities, Inc. Buys VCA Inc, Mobileye NV, Reynolds American Inc, Sells St Jude ...
|
Allied World Reports Q1 Adj. $0.53 vs $0.68 Est., Sales $639.183M vs $652.798 In Same Qtr. Last Year
|
Prem Watsa's Place in the Benjamin Graham Universe
|
Allied World Sharholders Approve Special Dividend $5/Share In Connection With Merger Transaction
|
Stocks Steven Cohen Continues to Buy
|
Allied World (AWH) Misses Earnings, Beats Revenues in Q4
|
Allied World Assurance Company Reports Q4 Operating EPS $0.48, Revenues $537.982M
|
Allied World Assurance misses by $0.15, misses on revenue
|
Allied World Assurance Spikes to High of $53.58 on Volume
|
7 High-Yield Companies With High Profitability
|
Recent Declines Are Opportunity to Buy Fairfax Financial Holdings
|
Top Insurance Stocks Set Up For New Buy Points
|
JP Morgan Downgrades Allied World Assurance Company Holdings, AG (Switzerland) to Neutral
|
'Canada's Warren Buffett' Prem Watsa Praises Trump, Forecasts Stock Pickers' Market
|
JMP Securities Downgrades Allied World Assurance to Market Perform
|
BMO Capital Upgrades Allied World Assurance to Market Perform
|
15 Biggest Mid-Day Gainers For Monday
|
Fairfax Financial to Acquire Allied World for $54/Share in Cash and Stock
|
Allied World Assurance declares $0.26 dividend
|
Macquarie Downgrades Allied World Assurance Company Holdings, AG (Switzerland) to Neutral
|
Allied World Assurance Company Holdings' (AWH) CEO Scott Carmilani on Q3 2016 Results - Earnings Call Transcript
|
Allied World Reports Q3 EPS $0.77 vs. Est. $0.60, Rev. $647.15M vs. Est. $612M
|
Reversals Off New Highs Point To Weak Market
|
6 Stocks With Growing Yield and Strong Returns
|
Allied World Pops to High of $41.25 on Volume
|
10 Notable Stocks Trading Ex-Dividend Friday, September 16
|
Allied World Assurance declares $0.26 dividend
|
15 Biggest Mid-Day Gainers For Wednesday
|
Allied World Assurance Reports Q2 Operating EPS $0.91
|
Notable earnings after Tuesday's close
|
The Impact Of Different Weighting Methods On My Dividend Portfolio
|
JP Morgan Initiates Coverage on Arrowhead Gold at Neutral
|
Allied World Assurance Launches Accounts Receivable Insurance in US
|
Allied World Assurance declares $0.26 dividend
|
Dividend Contenders: 18 Increases Expected By July 31
|
Allied World Assurance Company Holdings' (AWH) CEO Scott Carmilani on Q1 2016 Results - Earnings Call Transcript
|
Allied World Assurance Corp Approves New 2-Year $500M Buyback, Was Announced Earlier Today
|
Notable earnings after Tuesday's close
|
Benzinga's Top Downgrades
|
Allied World Assurance declares $0.26 dividend
|
AmTrust: Investment Income Can't Keep Up With Workers' Compensation Growth
|
Allied World Assurance Co Holdings' (AWH) CEO Scott Carmilani on Q4 2015 Results - Earnings Call Transcript
|
Allied World Assurance Reports Q4 Ops EPS $0.47 Vs Est $0.59
|
Piper Jaffray Initiates Coverage on Allied World Assurance at Overweight, Announces $44.00 PT
|
Allied World's (AWH) CEO Scott Carmilani on Q3 2015 Results - Earnings Call Transcript
|
Allied World Reports Q3 Loss $0.57 Vs Prior $0.31
|
Arrowhead Gold to Acquire Nuvo Energy Grid Inc.
|
Shares of Allied World Assurance Resume, Now Trading at $39.09
|
Daily Dividend: Company's Going Ex-Dividend Friday Of Next Week
|
Allied World Assurance declares $0.26 dividend
|
Allied World Assurance Co Holdings' (AWH) CEO Scott Carmilani on Q2 2015 Results -- Earnings Call Transcript
|
Allied World Assurance EPS of $0.10
|
AXIS Capital Counting on PartnerRe Merger, Costs Trouble - Analyst Blog
|
Allied World (AWH) Hits 52-Week High on FrameWRX Launch - Analyst Blog
|
9 Dividend Increases, June 1-12, 2015
|
Allied World Assurance declares $0.26 dividend
|
Will Allied World Assurance (AWH) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
|
Should You Add Allied World (AWH) to Your Portfolio Now? - Analyst Blog
|
Allied World Hits 52-Week High on Solid Q1 & Dividend Hike - Analyst Blog
|
Allied World Offers A Healthy Balance Sheet, But Market Conditions Are Tough
|
Allied World Increases Annual Dividend From $0.90 To $1.04/Share
|
Why You Shouldn't Bet Against Allied World Assurance (AWH) Stock - Tale of the Tape
|
Allied World's (AWH) CEO Scott Carmilani on Q1 2015 Results - Earnings Call Transcript
|
Allied World Assurance Company Holding Reports Q1 EPS $0.93 Vs Est $0.84, Sales $659M Vs Est $577.35M
|
Barclays Reinstates Equal-weight on Allied World Assurance, Announces $42.00 PT
|
Berkshire Hathaway to Acquire 8.7% Stake in Axalta Coating - Analyst Blog
|
Berkshire Hathaway Unit in Hot Water for Unfair Lending - Analyst Blog
|
ACE Limited Closes Fireman's Fund Acquisition, Stock Up - Analyst Blog
|
Progressive Closes ARX Buyout, Boosts Bundled Offering - Analyst Blog
|
Allied World (AWH) Expands Operations in Southeast Asia - Analyst Blog
|
RenaissanceRe Banks on Acquisitions, Cat Losses a Drag - Analyst Blog
|
Maiden Holdings Hits 52-Week High on Solid Q4 Results - Analyst Blog
|
Keefe, Bruyette & Woods Assumes Coverage On Allied World Assurance Company On Positive Outlook
|
RenaissanceRe Issues $300M Senior Notes Due 2025 - Analyst Blog
|
3 Stocks to Benefit From a Fed Rate Hike - Stocks in the News
|
Greenlight Capital Downgraded on Lackluster Results in Q4 - Analyst Blog
|
Travelers Scales 52-Week High on Solid Performance in Q4 - Analyst Blog
|
A.M. Best Affirms Validus Holdings' Ratings, Shares Constant - Analyst Blog
|
First American Expands Title Insurance, Buys TitleVest - Analyst Blog
|
ProAssurance's Capital Actions Look Good, Retentions Fall - Analyst Blog
|
eHealth Now a Strong Sell: Is Wider Q4 Loss Responsible? - Analyst Blog
|
Brown & Brown Enters ASR Program Worth $100 Million - Analyst Blog
|
Third Point Re Down to Strong Sell on Dismal Q4 Earnings - Analyst Blog
|
Allied World Assurance declares $0.225 dividend
|
Mercury General Down Post Rating Affirmation by A.M. Best - Analyst Blog
|
Allied World Announces Retirement of Scott Hunter from the Board of Directors
|
RLI Corp's Premium Improvement Initiatives Look Promising - Analyst Blog
|
Chubb Leads by Virtue of Superior Underwriting Acumen - Analyst Blog
|
ProAssurance Corp (PRA): What's in Store for Q4 Earnings? - Analyst Blog
|
Will Allied World Assurance Company Holdings, AG (AWH) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
|
Reinsurance Group Hits 52-Week High on Solid Q4 Earnings - Analyst Blog
|
American Financial Hits 52-Week High on Solid Q4 Earnings - Analyst Blog
|
First American Financial (FAF) in Focus: Stock Jumps 5.3% - Tale of the Tape
|
Everest Re at 52-Week High on Q4 Earnings Outperformance - Analyst Blog
|
McKesson Corporation Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
|
Allied World Assurance Holdings, AG (AWH) Q4 2014 Results - Earnings Call Transcript
|
Allied World Assurance Company Holdings Reports Q4 EPS $1.33 Vs Est $0.70 May Not COmpare, Revs $608.2M Vs Est $597.05M
|
Why Allied World Assurance (AWH) Stock Might be a Great Pick - Tale of the Tape
|
Europe: A Filter For 17 Interesting Stocks
|
Allied World Closes Buyout of Latin American Underwriters - Analyst Blog
|
XL Group in Talks to Buy Catlin, Increases Alternative Capital - Analyst Blog
|
Progressive to Insure Home & Auto with ARX Majority Stake - Analyst Blog
|
Kemper Boosts Auto Insurance with Alliance United Buyout - Analyst Blog
|
BMO Capital Downgrades Allied World Assurance Company Holdings, AG to Market Perform, Maintains $39.00 PT
|
ProAssurance (PRA) Raises Dividend & Approves Buyback - Analyst Blog
|
Allied World to Strengthen Specialty with LAU Acquisition - Analyst Blog
|
Allied World To Acquire Latin American Underwriters, No Terms Disclosed
|
Arrowhead Commences Trading on the Canadian Securities Exchange, Undertakes Shares for Debt ...
|
W.R. Berkley Beats Earnings, Revenues on High Premiums - Analyst Blog
|
Everest Re Q3 Earnings Beat Estimates, Top Line Grows - Analyst Blog
|
Allied World Assurance Company Holdings, AG Reports Q3 EPS of $0.61 vs $0.74 Est
|
Is Allied World (AWH) Worth Adding to Your Portfolio? - Analyst Blog
|
Will Chubb Corp (CB) Beat Q3 Earnings on Premium Growth? - Analyst Blog
|
3 P&C Insurers that Assure Upbeat Earnings - Earnings ESP
|
Allied World Arm to Expand Operations in Southeast Asia - Analyst Blog
|
Allied World Assurance Reports Purchase of Hong Kong, Sinagpore Operations of RSA for $215M
|
Chubb Q2 Earnings Miss on Elevated Claims, Guidance Trimmed - Analyst Blog
|
Allied World Q2 Earnings Miss on Lower Underwriting Income - Analyst Blog
|
Allied World Assurance Company Holdings, AG Reports Q2 EPS of $1.51 Which May Not Compare $0.78 Est; Revenue of $659.30M Which May Not Compare $564.70M Est
|
